Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112239 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Giada De Benedittis und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata", 00133 Rome, Italy. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Arthritis, Psoriatic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We aimed to identify an expression profile of lncRNAs potentially related to treatment response in Psoriatic arthritis (PsA) patients, to be used as potential genomic biomarkers predictors of drug treatment effectiveness. In addition, we evaluated a possible association between lncRNAs genetic variants and the response to therapy using the clinical parameter of Disease Activity Index. For the expression study, we collected 48 treated PsA patients, monitoring the treatment response for 12 months. We initially used PCR Array and, then, we validated the results with qRT-PCR. We also retrospectively genotyped 163 treated PsA patients. Firstly, we observed a significant difference in the expression level between Responder and non-Responder patients, of 4 lncRNAs in the group of PsA patients treated with TNFi and of 3 lncRNAs in the group of patients treated with IL17i. Then, we confirmed a significant decrease of MEG3 expression in non-Responder patients compared to Responders, also considering separately the single groups of patients treated with TNFi and IL17i. In addition, our results seem to highlight a potential dose-dependent effect of rs941576 (MEG3) variant allele on Disease Activity Index. Our study suggests a possible role of the lncRNA MEG3 in the treatment response to biological drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata", 00133 Rome, Italy.
- Rheumatology, Allergology and Clinical Immunology, Department of System Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
- Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata", 00133 Rome, Italy. Electronic address: a.latini@med.uniroma2.it.
- Department of Biomedicine and Prevention, Section of Genetics, University of Rome "Tor Vergata", 00133 Rome, Italy; School of Medicine, Department of Pharmacology, University of Nevada, 89557 Reno, USA; IRCCS NEUROMED,…
- UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
Zitieren
APA
De Benedittis, G., D'Antonio, A., Latini, A., Morgante, C., Conigliaro, P., Triggianese, P., Bergamini, A., Novelli, G., Ciccacci, C., Chimenti, M. S., & Borgiani, P. (2024). Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112239
Vancouver
De Benedittis G, D'Antonio A, Latini A, Morgante C, Conigliaro P, Triggianese P, et al. Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112239
BibTeX
@article{DeBenedittis2024,
author = {De Benedittis, Giada and D'Antonio, Arianna and Latini, Andrea and Morgante, Chiara and Conigliaro, Paola and Triggianese, Paola and Bergamini, Alberto and Novelli, Giuseppe and Ciccacci, Cinzia and Chimenti, Maria Sole and Borgiani, Paola},
title = {Study of lncRNAs expression profile in the response to biological drugs in Psoriatic Arthritis: MEG3 could be a potential genomic biomarker of therapy efficacy},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112239}
}
EUVIMED